Lee’s Pharm Licenses 1cBio’s OC-3 in China and Southeast Asia

Shots: 1cBio & Lee's Pharmaceutical have entered into a licensing agreement granting Lee's Pharm exclusive rights to develop & commercialize OC-3, a preclinical PARP1 inhibitor, in China & certain countries in SE Asia As per the deal, 1cBio will receive an upfront payment, development milestones & potential sales milestone payments totaling ~$27M, as well as…

ByRidhi Rastogi3 days ago

NEWS

MannKind and Rose Pharma Partner to Develop ROSE-010 Technosphere for Weight Management

Shots: Rose received exclusive global rights to MannKind’s Technosphere tech to develop & commercialize ROSE-010 Technosphere, a rapid-acting GLP-1 receptor agonist, with initial work focused on formulation re-establishment & optimization, followed by nonclinical & regulatory development MannKind will receive equity in Rose Pharma, the right to receive royalties on potential future net sales & board…

ByRidhi Rastogi3 days ago

NEWS

Novartis and Alteogen Partner for ALT-B4 to Advance SC Formulations of Multiple Products

Shots: Alteogen has entered into an option & license agreement with Novartis for the development & commercialization of SC products leveraging ALT-B4 powered by Alteogen's Hybrozyme tech As per the deal, Novartis can obtain exclusive rights to develop & commercialize SC formulations of multiple products using Alteogen’s ALT-B4, with Alteogen eligible for ~$3.223B in option…

ByRidhi RastogiSeptember 3, 2026

NEWS

Evotec and Plectonic Partner on Next-Generation T-Cell Engagers for Solid Tumors

Shots: Evotec and Plectonic Biotech have entered a research collaboration to explore a novel immunotherapy approach for solid tumors by combining Plectonic’s programmable Logibody technology with Evotec’s BiTco platform Plectonic’s Logibody uses multi-antigen tumor signatures to selectively activate T cells, while Evotec’s BiTco platform uses a non-blocking CD2 antibody to enhance T-cell activity, tumor killing…

ByRidhi RastogiSeptember 2, 2026

NEWS

Styx Biotechnologies Partner with ZoeNCure Therapeutics to Advance ADC Development

Shots: Styx Biotechnologies has entered into a strategic agreement with ZoeNCure Therapeutics to accelerate selected Styx ADC programs toward first-in-human clinical studies for multiple solid tumor indications The collaboration gives Styx a capital-efficient path to advance selected ADC assets through coordinated preclinical, CMC, regulatory & clinical activities while preserving opportunities for global development & strategic partnering As…

ByRidhi RastogiSeptember 2, 2026

NEWS

Simcere Zaiming Inks ~$1.53B Licensing Deal with Roche for SIM0660

Shots: Simcere Zaiming has entered into an exclusive global licensing agreement with Roche for the development & commercialization of SIM0660, a potential treatment of B-cell-mediated diseases As per the deal, Roche will acquire exclusive global rights to develop, manufacture, & commercialize SIM0660 in exchange for ~$1.53B in total, incl. $75M in upfront, as well as…

ByRidhi RastogiSeptember 2, 2026

NEWS

LEO Pharma to Acquire Global Rights to Tanabe Pharma’s Dersimelagon for ~$435M

Shots: LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) As per the deal, Tanabe Pharma will receive up to $435M in upfront & near-term milestone payments together with potential downstream milestones and tiered royalties on net…

ByRidhi RastogiAugust 18, 2026

NEWS

OmniAb and Eli Lilly Partner on New Ion Channel Discovery Program

Shots: OmniAb has entered a global collaboration & license agreement with Eli Lilly for a new ion channel program, leveraging OmniAb’s discovery & screening platform to identify next-generation therapeutics targeting ion channels The therapeutic target and modality remain undisclosed, while OmniAb will contribute its established expertise and technology in ion channel discovery & screening As…

ByRidhi RastogiAugust 17, 2026

NEWS

PTC Therapeutics to Acquire Sangamo Therapeutics’ ST-920 Gene Therapy Program

Shots: PTC Therapeutics has been selected as the winning bidder to acquire ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics through a competitive bankruptcy auction As per the terms, PTC Therapeutics will pay $111M upfront, with up to $100M in contingent milestone payments tied to certain regulatory approvals; expected to…

ByRidhi RastogiAugust 13, 2026

NEWS

Mereo BioPharma and Sentynl Therapeutics Ink ~$475M Pact for Alvelestat

Shots: Sentynl, a subsidiary of Zydus, has entered into an option & license agreement with Mereo for the US commercial & global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Sentynl will have an exclusive option to license alvelestat in the US, while Mereo retains ex-US commercial rights; Sentynl will also hold…

ByRidhi RastogiAugust 12, 2026

Lee’s Pharm Licenses 1cBio’s OC-3 in China and Southeast Asia

MannKind and Rose Pharma Partner to Develop ROSE-010 Technosphere for Weight Management

Novartis and Alteogen Partner for ALT-B4 to Advance SC Formulations of Multiple Products

Evotec and Plectonic Partner on Next-Generation T-Cell Engagers for Solid Tumors

Styx Biotechnologies Partner with ZoeNCure Therapeutics to Advance ADC Development

Simcere Zaiming Inks ~$1.53B Licensing Deal with Roche for SIM0660

LEO Pharma to Acquire Global Rights to Tanabe Pharma’s Dersimelagon for ~$435M

OmniAb and Eli Lilly Partner on New Ion Channel Discovery Program

PTC Therapeutics to Acquire Sangamo Therapeutics’ ST-920 Gene Therapy Program

Mereo BioPharma and Sentynl Therapeutics Ink ~$475M Pact for Alvelestat

Contact US

FOLLOW US